Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

An imbalance in glutamate levels has been linked to symptoms like exhaustion, difficulty concentrating, and depression. The FDA approved Spravato following a randomized, double-blind, placebo ...

J&J said Spravato works by targeting glutamate, the brain's most abundant chemical that sends messages from the brain to the body by stimulating nerve cells. While its exact mechanism remains ...

Esketamine has been shown to affect glutamate signaling in a matter of days, while oral antidepressants can take weeks. Spravato isn’t like the nasal spray you use when you have a cold.

Spravato targets glutamate in the brain, which is the most abundant excitatory neurotransmitter. Since there are some side effects, including sedation, respiratory depression and misuse ...

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate use of ...

At least 21 million adults in the U.S. have experienced depression. And, while oral antidepressant medications are a common treatment, they don't work for everyone. Now, the Food and Drug ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

SPRAVATO ® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain. 6 The mechanism by which esketamine exerts its antidepressant effect is ...